ScholarIQanswers from OpenAlex
Investigational New Drugs
JournalCitation impact & published research
Investigational New Drugs is a journal indexed in ScholarIQ from OpenAlex.
How many works does Investigational New Drugs have?
ScholarIQindexed works
Investigational New Drugs has 4,011 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Investigational New Drugs have?
ScholarIQcitation count
Investigational New Drugs has 108,399 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Investigational New Drugs?
ScholarIQh-index
Investigational New Drugs has an h-index of 115 in OpenAlex.
What is the article processing charge of Investigational New Drugs?
ScholarIQarticle processing charge
Investigational New Drugs lists an article processing charge of 4,390 USD in OpenAlex.
What is the OpenAlex record for Investigational New Drugs?
ScholarIQopenalex
The OpenAlex for Investigational New Drugs is on the source record.
What are the most-cited papers on Investigational New Drugs?
ScholarIQmost cited works
Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study
Stefan von Delius, Florian Eckel, Stefan Wagenpfeil, Martina Mayr, Konrad Stock, Frank Kullmann, Florian Obermeier, Johannes Erdmann, Renate Schmelz, Stefan Quasthoff, Helmuth Adelsberger, Rainer Bredenkamp, Roland M. Schmid, C. Lersch
Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors
Yasuhito Fujisaka, Takayasu Kurata, Kaoru Tanaka, Toshihiro Kudo, Kunio Okamoto, Junji Tsurutani, Hiroyasu Kaneda, Isamu Okamoto, Masayuki Namiki, Chifumi Kitamura, Kazuhiko Nakagawa
A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer
Michael Thomas, Parvis Sadjadian, Jens Kollmeier, Jamie Lowe, Paulette Mattson, J. Richard Trout, Michele Gargano, Myra L. Patchen, Richard M. Walsh, Martin Béliveau, Jean‐Francois Marier, Nandita Bose, Keith Gorden, Folker Schneller
Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers
Marie Bréchon, Marie Dior, Johann Dréanic, Bertrand Brieau, Marie‐Anne Guillaumot, Catherine Brézault, Olivier Mir, François Goldwasser, Romain Coriat
Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer
Nikita Volkov, Grigoriy A. Yanus, Alexandr O. Ivantsov, Fedor Moiseenko, Olga G. Matorina, Ilya V. Bizin, Vladimir Moiseyenko, Evgeny N. Imyanitov